Rule 3.19A.2

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Nanosonics Limited	
ABN	11 095 076 896	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Michael Kavanagh
Date of last notice	27 January 2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	a) Indirect Interest b) Indirect Interest c) Indirect Interest d) Direct Interest e) Indirect Interest	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<ul> <li>a) Performance Rights held in the Nanosonics Employee Share Option Plan.</li> <li>b) Performance Rights held in the Nanosonics Omnibus Equity Plan</li> <li>c) Options held in the Nanosonics Omnibus Equity Plan</li> <li>e) Restricted shares held by the trustee of the Nanosonics Employee Equity Trust</li> </ul>	
Date of change	18 March 2021	

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held prior to change	<ul> <li>a) 206,882 Performance Rights held in the Nanosonics Employee Share Option Plan.</li> <li>b) 188,775 Performance Rights held in the Nanosonics Omnibus Equity Plan.</li> <li>c) 964,703 Options held in the Nanosonics Omnibus Equity Plan.</li> <li>d) 1,018,363 Ordinary Shares.</li> <li>e) 19,547 Ordinary Shares</li> </ul>	
Class	<ul> <li>a) Performance Rights</li> <li>b) Performance Rights</li> <li>c) Options</li> <li>d) Ordinary Shares</li> <li>e) Ordinary Shares</li> </ul>	
Number acquired	143,298 Performance Rights 208,884 Share Appreciation Rights	
Number disposed	N/A	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	N/A	
No. of securities held after change	<ul> <li>a) 206,882 Performance Rights held in the Nanosonics Employee Share Option Plan.</li> <li>b) 332,073 Performance Rights held in the Nanosonics Omnibus Equity Plan.</li> <li>c) 208,884 Share Appreciation Rights held in the Nanosonics Omnibus Equity Plan.</li> <li>d) 964,703 Options held in the Nanosonics Omnibus Equity Plan.</li> <li>e) 1,018,363 Ordinary Shares.</li> <li>f) 19,547 Ordinary Shares</li> </ul>	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Issue of Performance Rights and Share Appreciation Rights under the terms and conditions of the Nanosonics Omnibus Equity Plan.	

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

## Part 3 - +Closed period

Were the interests in the securities or contracts detailed above	
traded during a <sup>+</sup> closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Director: Mr. Michael Kavanagh

Date: 18 March 2021

<sup>+</sup> See chapter 19 for defined terms.